GlassScriptPhysician profile
Maivys Longa
NPI 1568080828
$3,709.49
in general payments reported to CMS, 2019-2025
23 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $380 · 2023: $378 · 2024: $695 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.25 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $598.68 | 2024-2025 | Infuse, Scoutpro Osmolarity System, Miebo |
| Alcon Vision LLC | $571.71 | 2022-2025 | Precision7, Tryptyr, Clareon |
| Biotissue Holdings INC. | $570.42 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $297.80 | 2024-2025 | Xdemvy |
| Abbvie INC. | $239.65 | 2023 | |
| Sight Sciences, INC. | $218.41 | 2024-2025 | Tearcare System, Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $136.06 | 2021-2022 | |
| Allergan, INC. | $131.56 | 2021 | |
| Glaukos Corporation | $124.46 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $121.85 | 2024 | |
| Astellas Pharma US INC | $121.85 | 2025 | Izervay |
| Tearlab Corp | $121.43 | 2023 | Tearlab Osmolarity System |
| Coopervision INC. | $101.99 | 2023-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $100.00 | 2025 | Acuvue |
| Dompe US, INC. | $52.26 | 2024-2025 | Oxervate |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $49.23 | 2024 | Foresee Home |
| Oyster Point Pharma, INC. | $35.60 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $35.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.24 | 2022 | |
| Rxsight INC | $17.93 | 2022 | |
| Genentech USA, INC. | $16.39 | 2022 | |
| Eyevance Pharmaceuticals LLC | $13.74 | 2022 | |
| Ivantis, INC | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maivys Longa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.